International Journal for Multidisciplinary Research (IJFMR)
E-ISSN: 2582-2160 ● Website: www.ijfmr.com ● Email: editor@ijfmr.com

Antibiotics and Their Mode of Action: A Comprehensive Review of Mechanisms and Resistance Pathways

Rajanya Kundu[1], Rojina Khatun[2], Sudeshna Sengupta[3], Malavika Bhattacharya[4]

[1,2,3,4]Department of Biotechnology, Techno India University, EM-4, Salt Lake, Sector- V, Kolkata-700091 (India)

Abstract

Antibiotics are vital in combating infections by targeting bacteria and disrupting their growth. Understanding their various classes and modes of action helps us appreciate their role in healing. Bioremediation offers an environmentally friendly approach to removing antibiotics using microorganisms and plants. Techniques such as bioreactors, electrochemical systems, and hybrid methods can enhance pollution solutions. Biostimulation aids in cellular activity and tissue restoration, while ozone therapy is popular for facial rejuvenation. Phytoremediation, using plants like Myriophyllum aquaticum and Pistia stratiotes, effectively removes antibiotics from water, with various factors influencing its success. Integrated systems combine multiple methods to improve pollutant removal. Advanced techniques like metagenomics help analyze microbial communities and improve bioremediation outcomes. Nano-bioremediation enhances efficiency and bioavailability while addressing the limitations of traditional methods. Antibiotic biodegradation is crucial for environmental health, and wastewater treatment can involve ammonia-oxidizing bacteria. Despite successful bioremediation methods using diverse organisms, challenges such as antibiotic resistance and the potential for artificial wetlands to harbor resistance genes remain significant concerns.

KEYWORDS: bioremediation, antibiotic resistance, microbial, biodegradation, biostimulation, phytoremediation

Introduction

Antibiotics are potent medications that either kill or stop the growth of germs to treat bacterial infections. They fall into one of two categories: broad-spectrum or narrow-spectrum based on their effectiveness against different types of bacteria. Various antibiotics have different modes of action, interfering with important biochemical reactions in bacterial cells[1]. For example, β-lactam antibiotics interact with penicillin-binding proteins and sensitive enzymes, preventing cell division and possibly resulting in lysis[2]. The donor substrate analog theory of acyl-D-alanyl-D-alanine remains consistent with biochemical data, though multiple targets with varying sensitivities exist. Recent molecular biological approaches have significantly contributed to understanding antibiotic mechanisms[3]. While antibiotics are crucial for treating bacterial infections, they can also negatively impact the normal human

microbiota, necessitating careful consideration of their overall benefits and potential side effects[4].

HOW ANTIBIOTICS TREAT BACTERIAL INFECTION: -

Antibiotics are drugs that stop bacteria from growing or kill bacteria cells to treat bacterial infections[5]. They may be narrow-spectrum, focusing on particular bacteria, or broad-spectrum, impacting different kinds of bacterial organisms. Common antibiotics include tetracycline, doxycycline, and erythromycin. While effective against many infections, antibiotics do not treat viral or fungal infections. Antibiotic resistance is a serious threat to the ongoing efficacy of antibiotics due to their overuse and misuse[6]. To deal with this problem, optimizing treatment regimens is crucial. Mathematical modeling and genetic algorithms have identified improved regimens, such as high initial doses followed by tapered doses, which maximize bacterial eradication while minimizing antibiotic use. Combating antibiotic resistance requires changes in prescribing practices and behavior, including infection prevention measures like vaccination and hand washing[7].

COMBATING ANTIBIOTIC RESISTANCE: PRESCRIBING AND PREVENTION STRATEGIES

Combating antibiotic resistance requires a multifaceted approach involving changes in prescribing practices and preventive measures. Antimicrobial stewardship programs have been shown to improve patient outcomes and reduce resistance[8]. These initiatives work best when combined with infection prevention strategies, especially those involving hand hygiene. By preventing infections that might otherwise necessitate antibiotic treatment, vaccination helps to minimize the need for and abuse of antibiotics. It is crucial to educate patients, healthcare providers, and the general public about the appropriate use of antibiotics and good personal hygiene habits like handwashing[9]. To reduce resistance, antibiotic usage in food animals must be carefully monitored. Even with the development of new medications, antibiotic resistance will continue to pose a serious concern unless there are behavioral changes in the use of antibiotics and infection prevention[10].

ANTIBIOTIC EFFICACY OF TETRACYCLINE

Tetracyclines are broad-spectrum antibiotics widely used in medicine, particularly in dermatology. They are effective against various pathogens and valuable in treating conditions like atypical pneumonia, chlamydial infections, and Lyme disease[11]. In dermatology, tetracyclines are commonly prescribed for acne treatment, with doxycycline, minocycline, and sarecycline being notable examples. While tetracyclines are generally well-tolerated, they can cause side effects such as photosensitivity and are contraindicated during pregnancy and childhood due to potential dental staining and interference with bone growth. Importantly, tetracyclines may interfere with oral contraceptive efficacy, potentially leading to unintended pregnancies[12]. Dentists and other healthcare providers should inform women of childbearing age about this potential interaction and consider alternative treatments when appropriate[13].

DOXYCYCLINE: -COMMON ANTIBIOTIC INSIGHTS

Doxycycline, a semi-synthetic tetracycline antibiotic, is widely used due to its broad-spectrum activity and affordability. It is effective against various bacterial infections, including respiratory, genitourinary, and vector-borne diseases[14]. Doxycycline is rapidly absorbed in the gastrointestinal tract and widely

distributed in tissues. Besides its antimicrobial properties, doxycycline exhibits anti-inflammatory effects and inhibits matrix metalloproteinases, making it potentially beneficial for treating chronic wounds like diabetic foot ulcers. Common side effects include gastrointestinal disturbances and photosensitivity, with contraindications in pregnant women and young children[15]. Dosage recommendations vary by condition, typically ranging from 50 to 100 micrograms daily for acne and rosacea. Despite its long-standing use, doxycycline remains a valuable antibiotic in current clinical practice for treating various infectious and non-infectious conditions[16].

ERYTHROMYCIN: -COMMON ANTIBIOTICS INSIGHTS

Erythromycin is a widely used macrolide antibiotic effective against various bacterial infections. It is known for its safety profile and low toxicity, particularly in children[17]. The most common side effect is gastrointestinal intolerance, which can be mitigated through dosage adjustments and administration techniques. Erythromycin has shown promise in preventing exacerbations in COPD patients and reducing the frequency of common colds[18]. Despite its advantages, erythromycin has limitations, including a short serum elimination half-life and borderline activity against some gram-negative respiratory pathogens. Compared to tetracycline, erythromycin does not cause tooth enamel damage or in utero bone effects. While bacterial resistance to erythromycin has not been a significant clinical issue, allergic reactions, though rare, can occur[19].

Acyl-D-Alanyl-D-Alanine ANALOGUES IN BIOCHEMICAL TARGETING

The donor substrate analog theory of acyl-D-alanyl-D-alanine remains consistent with biochemical data on β-lactam antibiotics, though multiple targets with varying sensitivities exist[20]. These antibiotics inhibit bacterial cell wall biosynthesis by covalently modifying the sensitive enzymes' active site, creating penicillin-enzyme complexes. This happens because penicillin and the acyl-D-alanyl-D-alanine terminus of peptidoglycan strands share structural similarities[21]. Conformational analyses of peptide substrates and inhibitors reveal four probable backbone conformers for D-alanyl-D-alanine peptidases, with varying relative probabilities depending on the peptide. High turnover numbers require D-alanine at specific positions, while L-alanine analogs fall outside the conformational space of L-D-D tripeptides. The relationship between penicillin-binding proteins and their functions in cell growth and division is discussed, along with the bacteriostatic response observed in certain bacterial species[22].

MOLECULAR INSIGHTS INTO ANTIBIOTIC MECHANISMS

Molecular biological approaches have significantly contributed to understanding antibiotic mechanisms and resistance. These methods have elucidated biochemical resistance mechanisms and genetic dissemination routes among bacteria[23]. Advances in whole genome sequencing and high-throughput technologies have enabled the accumulation of large datasets amenable to bioinformatic analysis, facilitating the discovery of new antimicrobial resistance (AMR) signatures. Recent studies have identified new resistance gene families, uncovered structural features of the molecular processes underlying resistance, investigated relationships between various resistance mechanisms, and shed light on the role that resistance genes play in host biology[24]. This improved understanding has practical applications, including better interpretation of resistance phenotypes, more effective human therapy, promotion of prudent antibiotic use, and rational design of new drugs that evade existing resistance mechanisms or target unexploited bacterial processes[25].

ANTIBIOTICS AND HUMAN MICROBIOTA IMPACT

Although antibiotics are essential for treating bacterial infections, antibiotics can significantly disrupt the human gut microbiome, leading to various health consequences[26]. This disruption, known as dysbiosis, can result in decreased microbial diversity and create an environment conducive to antibiotic-resistant strains. Antibiotic exposure has been linked to increased risks of antibiotic-associated diarrhea, pseudomembranous colitis, and susceptibility to subsequent diseases[28]. The effects of antibiotics on the gut microbiome can persist for months to a year after treatment. Furthermore, antibiotic use has been associated with various conditions, including obesity, allergies, asthma, and altered metabolic processes[29]. To address these concerns to investigate antibiotic resistance in human gut metagenomes, researchers are using metagenomic techniques and investigating mechanisms of microbiota-mediated regulation against pathogenic infections. These initiatives seek to advance innovative antimicrobial therapy protocols and personalized medical approaches[30].

HOW ANTIBIOTICS TREAT IMPACTS DUE TO BACTERIAL CELL DESTRUCTION OR GROWTH INHIBITIONS:-

Antibiotics are crucial medications used to treat bacterial infections by either inhibiting bacterial growth or destroying bacterial cells. They target various cellular components, including the cell membrane, cell wall, protein synthesis, nucleic acid synthesis, and metabolic pathways. Specific antibiotics, such as penicillins and cephalosporins, act on the bacterial cell wall, while others like sulfamethoxazole and quinolones inhibit different cellular processes[31]. Recent research has focused on targeting bacterial cell division, particularly the FtsZ protein, as a promising strategy for developing new antibiotics. However, the widespread use of antibiotics has led to the emergence of antibiotic resistance, posing a significant threat to public health. This resistance occurs when bacteria evolve to reduce or eliminate the effectiveness of antibiotics, making infections more challenging to treat[32].

ANTIBIOTICS: - MECHANISMS AND IMPACT

Antibiotics are essential drugs that either kill bacterial cells (bactericidal) or prevent bacterial development (bacteriostatic) to treat bacterial illnesses. They are categorized as narrow-spectrum, which targets particular bacteria, or broad-spectrum, which affects a variety of bacterial organisms. Antibiotics have revolutionized medicine, nearly eradicating diseases like tuberculosis in developed countries. However, their overuse has led to the emergence of antibiotic-resistant bacteria, posing a significant global health threat. Common antibiotics include tetracycline, doxycycline, minocycline, erythromycin, and cephalosporin, which are used to treat various infections such as sinusitis, tonsillitis, and urinary tract infections. While antibiotics are highly effective against bacterial infections, they are not effective against viral infections like the common cold or influenza[33].

Antibiotics combat bacterial infections through various mechanisms, primarily targeting cell wall synthesis, protein production, and DNA replication. Beta-lactams, for instance, disrupt cell wall formation by interfering with peptidoglycan synthesis. Aminoglycosides inhibit protein synthesis by binding to ribosomes, while rifamycin prevents RNA messenger synthesis by altering RNA polymerase. However, bacteria have developed resistance mechanisms, including enzymatic degradation of antibiotics, alteration of target proteins, and changes in membrane permeability. Beta-lactamase production is a common resistance strategy against penicillin and cephalosporins. Other resistance mechanisms involve antibiotic-modifying enzymes and the synthesis of insensitive bacterial targets.

Understanding these resistance mechanisms is crucial for clinicians to make informed decisions about antibiotic usage and to combat the growing problem of antimicrobial resistance[34].

REVOLUTIONIZING MEDICINE: THE IMPACT OF ANTIBIOTICS

Antibiotics have revolutionized medicine since their discovery in the early 20th century, dramatically reducing mortality from infectious diseases and increasing life expectancy in developed countries. They have been particularly effective against tuberculosis, nearly eradicating it in the developed world. However, antibiotic-resistant bacteria have emerged as a result of antibiotic abuse and misuse, posing a serious threat to public health. This is especially concerning for tuberculosis, with drug-resistant strains becoming increasingly prevalent globally. Antimicrobial resistance is a major concern, according to the World Health Organization, which highlights the importance of using antibiotics responsibly. The creation of novel antibiotics is urgently needed to address this issue, and Application of tactics to fight resistant microorganisms[35].

ANTIBIOTICS FOR COMMON INFECTIONS

Antibiotics are widely used to treat various infections, with common types including tetracycline, doxycycline, minocycline, erythromycin, and cephalosporin. These antibiotics are effective against conditions such as sinusitis, tonsillitis, and urinary tract infections. Macrolides and doxycycline have shown immunomodulatory properties in treating chronic rhinosinusitis, even at subtherapeutic levels. For acute maxillary sinusitis, penicillin or amoxicillin are recommended for 7-14 days, although the benefits should be weighed against potential adverse effects[36]. Other antibiotic classes include aminoglycosides for serious infections like septicemia, and macrolides for various conditions. While antibiotics are effective in treating infections, their use may weaken the immune system over time, potentially leading to increased susceptibility to infections[37].

Antibiotics are commonly prescribed for various infections in primary care and emergency settings. Common indications include respiratory tract infections like acute bronchitis, community-acquired pneumonia (CAP), and COPD exacerbations, as well as urinary tract infections (UTIs), cellulitis, and intra-abdominal infections. However, studies have shown that antibiotic prescriptions often exceed guideline-recommended durations, particularly for respiratory infections[38]. To address antimicrobial overuse and resistance, recent guidelines recommend shorter courses of antibiotics for many common infections. For instance, 5-day courses are advised for COPD exacerbations, CAP, and cellulitis, while 3-5 days are recommended for uncomplicated UTIs in women. Adhering to these shorter durations can substantially reduce antibiotic exposure while maintaining treatment efficacy, potentially mitigating the development of antibiotic resistance[39].

ANTIBIOTICS: - MECHANISMS OF ACTION

Antibiotics target various essential bacterial processes to inhibit growth or cause cell death. They primarily affect cell wall synthesis, protein synthesis, DNA replication, RNA synthesis, and metabolic pathways. Specific targets include peptidoglycan synthesis, involving enzymes like MraY and MurG in the cytoplasmic membrane[40]. Other targets comprise teichoic acid, aminoacyl-tRNA synthetases, the lipid II cycle, and two-component systems. Antibiotics can also disrupt cell membrane structure and inhibit folic acid synthesis. The widespread use of antibiotics has led to the emergence of resistant bacteria, particularly methicillin-resistant Staphylococcus aureus (MRSA), posing significant clinical

challenges. To address this issue, researchers are exploring novel antibiotic targets and developing new drugs to combat resistant pathogens[41].

ANTIBIOTICS: DISRUPTION AND INHIBITION MECHANISMS

Antibiotics targeting folic acid synthesis, such as sulfonamides and trimethoprim, disrupt bacterial growth by inhibiting key enzymes in the folate biosynthesis pathway. Sulfonamides competitively inhibit dihydropteroate synthetase (DHPS), while trimethoprim inhibits dihydrofolate reductase. These antibiotics not only affect bacteria but can also impact plant growth by reducing folate content and inhibiting cell division in root apical meristems[42]. At sub-inhibitory concentrations, these drugs can modulate bacterial adhesion by altering fimbriation, hemagglutination, and epithelial cell adhesion in Escherichia coli. The study of folic acid metabolism and its inhibitors has led to the development of effective therapeutic compounds, demonstrating the successful interaction between biochemical research and empirical approaches in drug discovery. Understanding the mechanisms of these antibiotics has provided valuable insights into bacterial folate biosynthesis and potential targets for new drug development[43].

Antibiotics can serve dual purposes beyond their primary antimicrobial function. Some antibiotics have shown potential as corrosion inhibitors for metals, offering an eco-friendly alternative to traditional inhibitors. However, antibiotics themselves can be subject to inhibition. Certain front-line antibiotics, such as nitrofurantoin and sulfadiazine, have been found to inhibit organic anion transporters, potentially leading to drug-drug interactions[44]. Conversely, inhibitors can be developed to target bacterial resistance enzymes, potentially extending the lifespan of existing antibiotics. Interestingly, many antibiotics have been shown to inhibit bacterial ribosomal subunit formation, presenting a secondary target distinct from their well-known inhibition of translation. This dual-target mechanism contributes to their overall effectiveness in inhibiting cell growth and inducing cell death[45].

TARGETING FtsZ FOR BACTERIAL CELL WALL DISRUPTION

FtsZ, a prokaryotic cytoskeleton protein essential for bacterial cell division, has emerged as a promising target for novel antibacterial therapies. This GTPase forms a dynamic Z-ring at mid-cell, recruiting other proteins involved in cytokinesis[46]. Inhibiting FtsZ leads to filamentous cell growth and eventual lysis, making it an attractive target for drug development. Recent advances in screening methods and structure-based design have enabled the discovery of various FtsZ inhibitors, both natural and synthetic. These compounds target different aspects of FtsZ function, including its assembly dynamics and interactions with other proteins. While challenges remain in developing this new class of antibacterials, the therapeutic potential of FtsZ inhibitors continues to motivate researchers to find effective lead molecules with reduced toxicity[47].

Penicillins and cephalosporins are β-lactam antibiotics that target bacterial cell wall biosynthesis, specifically inhibiting the final cross-linking step. These antibiotics bind to penicillin-binding proteins, enzymes involved in cell wall formation, leading to cell wall destruction[48]. The bacterial cell wall is an ideal target for antimicrobial drugs due to its uniqueness and absence in mammalian cells, allowing for high target specificity and good safety profiles. However, bacteria have developed resistance mechanisms, including the production of β-lactamases that cleave the β-lactam ring and modifications of target proteins. Despite these challenges, β-lactam antibiotics remain clinically relevant, and efforts

continue to develop new, more effective versions, particularly cephalosporins, to combat emerging resistance[49].

CLASSIFICATION OF ANTIBIOTICS IN BROAD SPECTRUM: -

Antibiotics are classified as broad-spectrum when they are effective against both gram-positive and gram-negative bacteria, in contrast to narrow-spectrum antibiotics that target specific pathogens. Broad-spectrum antibiotics, such as tetracyclines and chloramphenicol, can also affect rickettsiae, larger viruses, and protozoa[50]. While these antibiotics are widely prescribed for acute respiratory tract infections, their use can lead to microbial dysbiosis in the skin and gut. Factors influencing broad-spectrum antibiotic prescribing include physician specialty, geographic region, and patient demographics. Evolutionarily, broad-spectrum antibiotics likely developed in dominant microbes that could afford to target diverse competitors, while narrow-spectrum toxins evolved to focus on key competitors. The choice between broad- and narrow-spectrum antibiotics should consider the potential impact on the microbiome and the specific pathogens involved[51].

BROAD-SPECTRUM ANTIBIOTICS – TETRACYCLINES:-

Tetracyclines are broad-spectrum antibiotics widely used in human and animal medicine, but their overuse has led to significant resistance in non-target bacteria like Escherichia coli. However, new third-generation tetracyclines, including eravacycline, omadacycline, and tigecycline, have been developed to overcome common resistance mechanisms and maintain efficacy against various pathogens[52]. These newer agents offer potential benefits for patients with specific clinical needs, such as β-lactam allergies or renal insufficiency. Despite their broad utility, the use of tetracyclines and other broad-spectrum antibiotics may have unintended consequences. A study found that patients prescribed tetracyclines had a higher likelihood of developing irritable bowel syndrome within 12 months, even after controlling for sex and comorbid conditions. This highlights the need for judicious use of broad-spectrum antibiotics and further research into their long-term effects on gut health[53].

The emergence of third-generation tetracyclines represents a significant advancement in combating antibiotic resistance. Eravacycline, omadacycline, tigecycline, and sarecycline are the newest members of this class, overcoming common tetracycline resistance mechanisms[54]. These antibiotics exhibit broad-spectrum activity against Gram-positive, Gram-negative, anaerobic, and atypical pathogens, including many drug-resistant strains. They offer effective treatment options for various infections, particularly in patients with unmet clinical needs such as β-lactam allergies or renal insufficiency. Structural optimizations have led to subgroups like glycylcyclines, aminomethylcyclines, and fluorocyclines, each with unique properties. Notably, sarecycline has a narrow spectrum, specifically targeting Cutinebacterium acne for acne treatment. These new tetracyclines not only address antibiotic resistance but also show potential for non-antibiotic applications, such as anti-inflammatory effects[55].

BROAD-SPECTRUM BACTERIAL EFFECTS

Recent research has explored various approaches to developing broad-spectrum antibacterial agents. Targeting bacterial RNA polymerase σ70 with antisense antibacterials has shown promise as a potential strategy for broad-spectrum inhibition. Biosurfactants, such as rhamnolipids and plant-derived surfactants, have demonstrated effectiveness in reducing biofilm biomass across multiple bacterial species, outperforming traditional antibiotics in some cases. Small synthetic peptides with antibiofilm

activity have emerged as another promising avenue, showing the ability to inhibit developed biofilms, kill multiple bacterial species, and synergize with existing antibiotics. Additionally, benzo pyridone cyanoacetates have been identified as potential broad-spectrum antibacterial candidates, exhibiting rapid sterilization capacity, low resistance trends, and the ability to eliminate bacterial biofilms and disrupt membrane integrity. These diverse approaches offer new possibilities for combating multidrug-resistant bacterial infections[56].

BROAD-SPECTRUM ANTIBIOTICS – CHLORAMPHENICOL

Chloramphenicol, a broad-spectrum antibiotic discovered in 1947, has been widely used for various bacterial infections. Despite its efficacy, its usage has been limited due to side effects. A systematic review found higher mortality rates with chloramphenicol for respiratory tract infections and meningitis compared to other antibiotics. It is no longer the drug of choice for any infection but may be considered as an alternative therapy in certain conditions. Chloramphenicol's pharmacokinetics are complex, with erratic serum concentrations, especially in patients with liver disease. Major adverse effects include dose-related and non-dose-related toxicities. The drug's use is further complicated by interactions with other medications like phenytoin and rifampin. Despite these limitations, chloramphenicol might still have a role in treating multi-drug-resistant bacterial infections[57].

ANTIBIOTICS AND MICROBIAL DYSBIOSIS

Antibiotics, widely prescribed for respiratory and urinary tract infections, can significantly alter the gut microbiota composition and diversity. These changes can occur rapidly and may persist for weeks or even months after treatment cessation. Different antibiotics have varying effects on specific bacterial populations; for instance, doxycycline decreases Bifidobacterium diversity, while clarithromycin reduces Enterobacteria, Bifidobacterium, and Lactobacillus populations[58]. The impact of antibiotics extends beyond the gut, affecting oral, respiratory, skin, and vaginal microbiota. These alterations in microbial communities can have long-lasting consequences, potentially contributing to various health issues such as obesity, behavioral changes, allergies, and autoimmune disorders. While antibiotics have transformed previously lethal infections into manageable diseases, their effects on the microbiome highlight the need for judicious use and further research into potential long-term health implications[59].

INFLUENCES ON ANTIBIOTIC PRESCRIBING

Broad-spectrum antibiotic prescribing for acute respiratory tract infections is influenced by various factors. Physician specialty plays a significant role, with internists more likely to prescribe broad-spectrum antibiotics compared to general and family practitioners[59]. The geographic region also impacts prescribing patterns, with higher rates observed in the Northeast and South compared to the West. Patient demographics, including age, gender, and social category, affect antibiotic choice. Younger patients and those with private insurance are more likely to receive broad-spectrum antibiotics. Additionally, prescriber characteristics such as age and gender influence antibiotic selection. Notably, inappropriate prescribing is common, with antibiotics often prescribed for conditions where they provide no benefit[60].

EVOLUTION OF ANTIBIOTIC STRATEGIES: -

Bacteria employ diverse warfare strategies, including broad-spectrum antibiotics and narrow-spectrum

toxins, to compete in microbial communities. Evolutionary modeling suggests that broad-spectrum toxins are favored when microbes are abundant and can produce large quantities, while narrow-spectrum toxins allow for focused attacks on key competitors[61]. This diversity in antimicrobial mechanisms is shaped by factors such as cell density, nutrient availability, and spatial arrangement. The evolution of these weapons has significant implications for microbial community dynamics and human health. Understanding the ecological and evolutionary drivers of bacterial warfare is crucial for manipulating microbiomes and developing new antibiotics. The abundance and variety of microbial defense systems highlight the considerable energy investment microbes make in producing these biological weapons[62].

REVOLUTIONIZING MEDICINE: THE IMPACT OF ANTIBIOTICS ON TUBERCULOSIS

Since their discovery in the early 20th century, antibiotics have transformed medicine, significantly lowering infectious illness mortality and raising life expectancy in developed nations. In the developed world they have been very successful in eradicating tuberculosis[63]. However, antibiotic-resistant bacteria have emerged as a result of antibiotic abuse and misuse, posing a serious threat to public health. Given the rising prevalence of drug-resistant forms of tuberculosis worldwide, this is particularly worrying. Antimicrobial resistance is a major concern, according to the World Health Organization, which highlights the importance of using antibiotics responsibly. The creation of novel antibiotics and the application of tactics to counteract resistant microorganisms are urgently needed to address this issue[64].

ANTIBIOTICS: - SCOPE AND LIMITATIONS

Antibiotics can not cure fungal or viral illnesses, but they are effective against bacterial infections. Antibiotics, which suppress or kill germs, were discovered in the early 20th century and have saved many lives[65]. However improper use of them, especially for viral illnesses like the flu and colds, has resulted in the appearance of bacterial strains resistant to antibiotics. Antibiotics kill bacteria or inhibit their growth through a variety of processes, but they don't work on viruses[66]. Public health is seriously threatened by the emergence of antibiotic resistance since it diminishes the efficacy of these essential drugs. Using antibiotics sparingly and only when required for bacterial infections—avoid using them for viral illnesses like the flu or the common cold—is crucial to addressing this problem[67].

ANTIBIOTIC RESISTANCE CRISIS

Antibiotic resistance, driven by overuse and misuse of antibiotics, poses a significant global health threat. This issue is particularly prevalent in Asian regions due to easy access to strong antibiotics without prescriptions. The consequences include severe infections, complications, longer hospital stays, and increased mortality. While antibiotic resistance occurs naturally, human behavior has accelerated its development[68]. The problem affects both healthcare professionals and the general public, involving complex biochemical and genetic pathways in microbes. To combat this issue, judicious antibiotic use is crucial. Experts emphasize the need for preventive measures, such as immunization and public health initiatives, alongside the development of new antibiotics. Various strategies have been proposed to address and reverse antibiotic resistance[69].

The widespread use of antibiotics has led to the emergence of antibiotic resistance, posing a significant threat to public health. This global issue results in prolonged illnesses, higher mortality rates, and increased healthcare costs. Factors contributing to resistance include inappropriate prescriptions, over-

the-counter availability, and use in agriculture. The problem is exacerbated by patients' expectations and misconceptions about antibiotics. To combat this threat, multifaceted approaches are necessary, including infection control measures, antibiotic stewardship programs, and public awareness campaigns. Health communication scholars can contribute to efforts to preserve the effectiveness of current antibiotics. Without urgent action, we may be approaching a post-antibiotic era, with serious implications for global health[70].

OPTIMIZING ANTIBIOTIC TREATMENT REGIMENS

Optimizing antibiotic treatment regimens is crucial in addressing antibiotic resistance. Mathematical modeling and evolutionary algorithms have been used to identify improved dosing strategies that minimize antibiotic use while maximizing bacterial eradication. These approaches have shown that regimens with high initial doses followed by tapering can be more effective than traditional fixed-dose treatments[71]. The optimization of dosing schedules should consider the specific killing patterns of antibiotics, such as concentration-dependent or time-dependent effects. Key targets for implementing optimal antimicrobial treatment in veterinary practice include reducing overall consumption, improving diagnostic testing, prudent use of critically important antibiotics, and optimizing dosage regimens. These strategies, along with species- and disease-specific recommendations, can help minimize resistance selection while maintaining treatment efficacy across various animal species and conditions[72].

OPTIMIZING ANTIBIOTIC REGIMENS WITH MATHEMATICAL MODELING: -

Mathematical modeling and evolutionary algorithms have emerged as powerful tools for optimizing antibiotic treatment regimens to combat antibiotic resistance[73]. Studies have shown that these approaches can identify improved dosing strategies that minimize antibiotic use while maximizing bacterial eradication. A common trend observed across these studies is the effectiveness of regimens consisting of a high initial dose followed by tapered doses. These optimized treatments consistently outperform traditional fixed-daily-dose regimens, reducing treatment failure rates by an average of 30% while using the same total amount of antibiotics[74]. The optimization approaches consider various factors, including different levels of bacterial resistance, administration routes, and coinfections with multiple bacterial strains. By formulating antibiotic dosing as a multi-objective optimization problem, researchers have successfully designed shorter treatments with improved success rates and reduced drug use[75].

ANTIBIOTIC MECHANISMS IN AI

Antibiotics are crucial in combating bacterial infections, but their effectiveness is threatened by antimicrobial resistance. The three major classes of bactericidal antibiotics induce cell death through the production of hydroxyl radicals, regardless of their specific drug-target interactions. Understanding the mechanisms of antibiotic action and resistance is essential for clinical practice[76]. Artificial intelligence (AI) is increasingly being applied to accelerate antibiotic discovery, addressing the urgent need for new antimicrobials. AI-driven approaches are being used to predict antimicrobial activity, determine drug-likeness traits, and design novel molecules. The classification and mode of action of antibiotics have been further elucidated through molecular biological approaches, providing insights into their effects on both pathogenic bacteria and the human microbiota[77].

OPTIMIZING ANTIBIOTIC REGIMENS WITH GENETIC ALGORITHMS

Mathematical modeling and genetic algorithms have been used to optimize antibiotic treatment regimens, addressing the challenge of antibiotic resistance. Studies have identified improved regimens that maximize bacterial eradication while minimizing antibiotic use[78]. These optimized treatments often involve a high initial dose followed by tapered doses, which consistently outperform traditional fixed-dose regimens. Researchers have utilized in vitro experiments, animal models, and mathematical simulations to develop and validate these optimized regimens[79]. The approach of combining biological data from insect infection models with mathematical modeling and artificial intelligence has proven effective in determining optimal dosage regimens. These studies demonstrate the potential for improved antibiotic treatments that enhance efficacy, reduce total drug use, and potentially mitigate the development of antibiotic resistance[80].

Reference

1. Etebu, E., & Arikekpar, I. (2016). Antibiotics : Classification and mechanisms of action with emphasis on molecular perspectives.
2. Etebu, E., & Arikekpar, I. (2016). Antibiotics : Classification and mechanisms of action with emphasis on molecular perspectives. . Etebu, E., & Arikekpar, I. (2016). Antibiotics : Classification and mechanisms of action with emphasis on molecular perspectives.
3. Mansour, S.R., & Abdel-Gelil, O.E. (2019). Tetracycline and toxicity induced. *Gastroenterology & Hepatology: Open Access*. Mansour, S.R., & Abdel-Gelil, O.E. (2019). Tetracycline and toxicity induced. *Gastroenterology & Hepatology: Open Access*.
4. Pasarkar, N., Waghmare, S.A., & Kamble, H.A. (2021). ANTIBIOTIC RESISTANCE: A REVIEW. *International Journal of Engineering Applied Sciences and Technology*.
5. Septimus, E.J. (2018). Antimicrobial Resistance: An Antimicrobial/Diagnostic Stewardship and Infection Prevention Approach. *The Medical clinics of North America, 102 5*, 819-829.
6. Gabutti, G. (2022). Available evidence and potential for vaccines for reduction in antibiotic prescriptions. *Human Vaccines & Immunotherapeutics, 18*.
7. Lee, C., Cho, I.H., Jeong, B.C., & Lee, S.H. (2013). Strategies to Minimize Antibiotic Resistance. *International Journal of Environmental Research and Public Health, 10*, 4274 - 4305
8. Amichai, B., & Grunwald, M. (1998). Tetracyclines and their uses in dermatology. *Journal of Dermatological Treatment, 9*, 221-229.
9. Graber, E.M. (2021). Treating acne with the tetracycline class of antibiotics: A review. *Dermatological Reviews*.
10. Jodh, R., Tawar, M.G., Gomkale, K., Jari, S., Toply, J., & Faisal, N. (2022). An Updated Review on Doxycycline. *Research Journal of Pharmacology and Pharmacodynamics*.
11. Xu, D.H., Zhu, Z., & Fang, Y. (2017). The Effect of a Common Antibiotics Doxycycline on Non-Healing Chronic Wound. *Current pharmaceutical biotechnology, 18 5*, 360-364.
12. Leggat, P.A. (2009). Safety and Efficacy of Doxycycline. *Clinical Medicine and Therapeutics, 2009*, 1069-1072.
13. Zyryanov, S.K., Golub, A.V., & Kozlov, R.S. (2020). Doxycycline in the current clinical practice.
14. Suzuki, T., Yanai, M., Yamaya, M., Satoh-Nakagawa, T., Sekizawa, K., Ishida, S., & Sasaki, H. (2001). Erythromycin and common cold in COPD. *Chest, 120 3*, 730-3.

15. Courvalin, P., & Cuot, P.T. (2001). Minimizing potential resistance: the molecular view. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 33 Suppl 3*, S138-46.
16. Van Camp, P., Haslam, D.B., & Porollo, A.A. (2020). Bioinformatics Approaches to the Understanding of Molecular Mechanisms in Antimicrobial Resistance. *International Journal of Molecular Sciences, 21*. Darby, E.M., Trampari, E., Siasat, P., Gaya, M.S., Alav, I., Webber, M.A., & Blair, J.M. (2022). Molecular mechanisms of antibiotic resistance revisited. *Nature Reviews Microbiology, 21*, 280-295.
17. Lathakumari, R.H., Vajravelu, L.K., Satheesan, A., Ravi, S., & Thulukanam, J. (2024). Antibiotics and the gut microbiome: Understanding the impact on human health. *Medicine in Microecology*.
18. Keeney, K.M., Yurist-Doutsch, S., Arrieta, M.C., & Finlay, B.B. (2014). Effects of antibiotics on human microbiota and subsequent disease. *Annual review of microbiology, 68*, 217-35.
19. White, A.C., & Kang, G. (2015). Antibiotics, microbiota and health: are there dangers hiding in plain sight? *Current opinion in infectious diseases, 28 5*, 455-6.
20. Lathakumari, R.H., Vajravelu, L.K., Satheesan, A., Ravi, S., & Thulukanam, J. (2024). Antibiotics and the gut microbiome: Understanding the impact on human health. *Medicine in Microecology*.
21. Kırmusaoğlu, S., Gareayaghi, N., & Kocazeybek, B.S. (2019). Introductory Chapter: The Action Mechanisms of Antibiotics and Antibiotic Resistance. *Antimicrobials, Antibiotic Resistance, Antibiofilm Strategies and Activity Methods*.
22. Khan, F.N. (2018). Antibiotics Classification and Visual Target Sites for Bacterial Inhibitio. Sass, P., & Brötz-Oesterhelt, H. (2013). Bacterial cell division as a target for new antibiotics. *Current opinion in microbiology, 16 5*, 522-30.
23. Begum, S., Begum, T., Rahman, N., & Khan, R.A. (2021). A review on antibiotic resistance and way of combating antimicrobial resistance.
24. Mansour, S.R., & Abdel-Gelil, O.E. (2019). Tetracycline and toxicity induced. *Gastroenterology & Hepatology: Open Access*.
25. Dhakad, G.G., Patil, R.V., Girase, D.S., Amrutkar, S.P., & Jain, R.S. (2022). Review on Antibiotics. *Asian Journal of Research in Chemistry*.
26. Anggita, D., Nurisyah, S., & Wiriansya, E.P. (2022). Mekanisme Kerja Antibiotik: Review Article. *UMI Medical Journal.*
27. Kapoor, G., Saigal, S., & Elongavan, A. (2017). Action and resistance mechanisms of antibiotics: A guide for clinicians. *Journal of Anaesthesiology, Clinical Pharmacology, 33*, 300 - 305.
28. Lees, K.A., Orlandi, R.R., Oakley, G.M., & Alt, J.A. (2020). The Role of Macrolides and Doxycycline in Chronic Rhinosinusitis. *Immunology and allergy clinics of North America, 40 2*, 303-315.
29. Williams Jr, J., Aguilar, C., Cornell, J.E., Chiquette E. Dolor, R., Makela, M., Holleman, D.R., & Simel, D. (2003). Antibiotics for acute maxillary sinusitis. *The Cochrane database of systematic reviews, 2*, CD000243.
30. Zgheib, & Saab, Y. (2021). Antibiotics in Lebanese Surface Waters: Estimation of Population Exposure and Identification of High-Risk Drugs.
31. Pouwels, K.B., Hopkins, S., Llewelyn, M.J., Walker, A.S., McNulty, C.A., & Robotham, J.V. (2019). Duration of antibiotic treatment for common infections in English primary care: cross sectional analysis and comparison with guidelines. *The BMJ, 364*.

32. Lee, R.A., Centor, R.M., Humphrey, L.L., Jokela, J.A., Andrews, R., & Qaseem, A. (2021). Appropriate Use of Short-Course Antibiotics in Common Infections: Best Practice Advice from the American College of Physicians. *Annals of Internal Medicine, 174*, 822 - 827.
33. Liu, Y., & Breukink, E. (2016). The Membrane Steps of Bacterial Cell Wall Synthesis as Antibiotic Targets. *Antibiotics, 5*.
34. Lade, H., & Kim, J. (2021). Bacterial Targets of Antibiotics in Methicillin-Resistant Staphylococcus aureus. *Antibiotics, 10*.
35. Saleem, M., Deters, B., Bastide, A.D., & Korzen, M. (2019). Antibiotics Overuse and Bacterial Resistance. *Annals of Microbiology and Research*.
36. Liu, Y., & Breukink, E. (2016). The Membrane Steps of Bacterial Cell Wall Synthesis as Antibiotic Targets. *Antibiotics, 5*.
37. Feng, G., Zou, W., & Zhong, Y. (2022). Sulfonamides Repress Cell Division in the Root Apical Meristem by Inhibiting Folates Synthesis. *Journal of Hazardous Materials Advances*.
38. Karthikeyan, S. (2016). Drugs/Antibiotics as potential corrosion inhibitors for Metals-A Review.
39. Lu, X., Chan, T., Zhu, L., Bao, X., Velkov, T., Zhou, Q.T., Li, J., Chan, H., & Zhou, F. (2018). The inhibitory effects of eighteen front-line antibiotics on the substrate uptake mediated by human Organic anion/cation transporters, Organic anion transporting polypeptides and Oligopeptide transporters in in vitro models. *European Journal of Pharmaceutical Sciences, 115*, 132–143.
40. Liu, Y., Li, R., Xiao, X., & Wang, Z. (2018). Molecules that Inhibit Bacterial Resistance Enzymes. *Molecules, 24*.
41. Champney, W.S. (2006). The other target for ribosomal antibiotics: inhibition of bacterial ribosomal subunit formation. *Infectious disorders drug targets, 6 4*, 377-90.
42. Hurley, K.A., Santos, T.M., Nepomuceno, G., Huynh, V., Shaw, J.T., & Weibel, D.B. (2016). Targeting the Bacterial Division Protein FtsZ. *Journal of medicinal chemistry, 59 15*, 6975-98.
43. Li, X., & Ma, S. (2015). Advances in the discovery of novel antimicrobials targeting the assembly of bacterial cell division protein FtsZ. *European journal of medicinal chemistry, 95*, 1-15 .
44. Schaffner-Barbero, C., Martín-Fontecha, M., Chacón, P., & Andreu, J.M. (2012). Targeting the assembly of bacterial cell division protein FtsZ with small molecules. *ACS chemical biology, 7 2*, 269-77.
45. Fisher, J.F., & Mobashery, S. (2019). Constructing and deconstructing the bacterial cell wall. *Protein Science, 29*, 629 - 646.
46. Bush, K. (2013). Introduction to Antimicrobial Therapeutics Reviews: The bacterial cell wall as an antimicrobial target. *Annals of the New York Academy of Sciences, 1277*.
47. Goo, K.S., & Sim, T.S. (2011). Designing new β-lactams: implications from their targets, resistance factors and synthesizing enzymes. *Current computer-aided drug design, 7 1*, 53-80.
48. Steinman, M.A., Landefeld, C.S., & Gonzales, R. (2003). Predictors of broad-spectrum antibiotic prescribing for acute respiratory tract infections in adult primary care. *JAMA, 289 6*, 719-25 . Steinman, M.A., Landefeld, C.S., & Gonzales, R. (2003). Predictors of broad-spectrum antibiotic prescribing for acute respiratory tract infections in adult primary care. *JAMA, 289 6*, 719-25.
49. Palmer, J.D., & Foster, K.R. (2022). The evolution of spectrum in antibiotics and bacteriocins. *Proceedings of the National Academy of Sciences of the United States of America, 119*. Grada, A., & Bunick, C.G. (2021). Spectrum of Antibiotic Activity and Its Relevance to the Microbiome. *JAMA network open, 4 4*, e215357.

50. Hussain, T., Jamal, M., Nighat, F., & Andleeb, S. (2014). Broad Spectrum Antibiotics and Resistance in Non-target Bacteria: An Example from Tetracycline.
51. LaPlante, K.L., Dhand, A., Wright, K.N., & Lauterio, M. (2022). Re-establishing the utility of tetracycline-class antibiotics for current challenges with antibiotic resistance. *Annals of Medicine, 54*, 1686 - 1700. Villarreal, A., Aberger, F.J., Benrud, R., & Gundrum, J.D. (2012). Use of broad-spectrum antibiotics and the development of irritable bowel syndrome. *WMJ : official publication of the State Medical Society of Wisconsin, 111 1*, 17-20.
52. Rusu, A., & Buta, E.L. (2021). The Development of Third-Generation Tetracycline Antibiotics and New Perspectives. *Pharmaceutics, 13*.
53. Bai, H., Bo, X., & Wang, S. (2012). Targeting bacterial RNA polymerase σ70 for development of broad-spectrum antisense antibacterials. *Recent patents on anti-infective drug discovery, 7 3*, 213-22.
54. Quinn, G., Maloy, A.P., Banat, M.M., & Banat, I.M. (2013). A Comparison of Effects of Broad-Spectrum Antibiotics and Biosurfactants on Established Bacterial Biofilms. *Current Microbiology, 67*, 614 - 623.
55. Pletzer, D., & Hancock, R.E. (2016). Antibiofilm Peptides: Potential as Broad-Spectrum Agents. *Journal of Bacteriology, 198*, 2572 - 2578.
56. Zhang, J., Tan, Y., Li, S., Battini, N., Zhang, S., Lin, J., & Zhou, C. (2023). Discovery of benzopyridone cyanoacetates as new type of potential broad-spectrum antibacterial candidates. *European journal of medicinal chemistry, 265*, 116107.
57. Ferrer, M., Méndez-García, C., Rojo, D., Barbas, C., & Moya, A. (2017). Antibiotic use and microbiome function. *Biochemical Pharmacology, 134*, 114–126.
58. Elvers, K.T., Wilson, V., Hammond, A., Duncan, L.J., Huntley, A.L., Hay, A.D., & van der Werf, E.T. (2020). Antibiotic-induced changes in the human gut microbiota for the most commonly prescribed antibiotics in primary care in the UK: a systematic review. *BMJ Open, 10*.
59. Ferrer, M., Méndez-García, C., Rojo, D., Barbas, C., & Moya, A. (2017). Antibiotic use and microbiome function. *Biochemical Pharmacology, 134*, 114–126.
60. Neuman, H., Forsythe, P., Uzan, A., Avni, O., & Koren, O. (2018). Antibiotics in early life: dysbiosis and the damage done. *FEMS Microbiology Reviews, 42*, 489–499.
61. Hicks, L.A., Bartoces, M.G., Roberts, R., Suda, K.J., Hunkler, R.J., Taylor, T.H., & Schrag, S. (2015). US outpatient antibiotic prescribing variation according to geography, patient population, and provider specialty in 2011. *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 60 9*, 1308-16.
62. Blommaert, A., Coenen, S., Gielen, B., Goossens, H., Hens, N., & Beutels, P. (2013). Patient and prescriber determinants for the choice between amoxicillin and broader-spectrum antibiotics: a nationwide prescription-level analysis. *The Journal of antimicrobial chemotherapy, 68 10*, 2383-92.
63. Palmer, J.D., & Foster, K.R. (2022). The evolution of spectrum in antibiotics and bacteriocins. *Proceedings of the National Academy of Sciences of the United States of America, 119*.
64. Lawani-Luwaji, E.U. (2024). The Antibiotic Era: A Golden Age and Its Challenges. *British Journal of Multidisciplinary and Advanced Studies*.
65. Johnson, T.D. (2010). Antibiotics: Knowing when they're not needed. *The Nation's Health, 40*, 15-15. Hildreth, C.J., Burke, A.E., & Glass, R.M. (2009). JAMA patient page. Inappropriate use of antibiotics. *JAMA, 302 7*, 816.

66. Begum, S., Begum, T., Rahman, N., & Khan, R.A. (2021). A review on antibiotic resistance and way of combating antimicrobial resistance.
67. Hildreth, C.J., Burke, A.E., & Glass, R.M. (2009). JAMA patient page. Inappropriate use of antibiotics. *JAMA, 302 7*, 816.
68. Mittal, A., Bhardwaj, R., Mishra, P., & Rajput, S.K. (2020). Antimicrobials Misuse/Overuse: Adverse Effect, Mechanism, Challenges and Strategies to Combat Resistance. *The Open Biotechnology Journal*.
69. Ousaid, A., Akrim, J., & Khayati, Y. (2020). Overuse of antibiotics as a key driver to antibiotic resistance in Morocco: A short review with potential solutions. *The International Arabic Journal of Antimicrobial Agents, 10*.
70. Smith, R.A., M'ikanatha, N.M., & Read, A.F. (2015). Antibiotic Resistance: A Primer and Call to Action. *Health Communication, 30,* 309 – 314 .
71. Goranova, M., Ochoa, G., Maier, P., & Hoyle, A. (2022). Evolutionary optimisation of antibiotic dosing regimens for bacteria with different levels of resistance. *Artificial intelligence in medicine, 133*, 102405
72. Paterson, I., Hoyle, A., Ochoa, G., Baker-Austin, C., & Taylor, N.G. (2016). Optimising Antibiotic Usage to Treat Bacterial Infections. *Scientific Reports,6*.
73. Guardabassi, L., Apley, M.D., Olsen, J.E., Toutain, P.L., & Weese, S. (2018). Optimization of Antimicrobial Treatment to Minimize Resistance Selection. *Microbiology Spectrum, 6*
74. Goranova, M., Ochoa, G., Maier, P., & Hoyle, A. (2022). Evolutionary optimisation of antibiotic dosing regimens for bacteria with different levels of resistance. *Artificial intelligence in medicine, 133*, 102405. Ochoa, G., Christie, L.A., Brownlee, A.E., & Hoyle, A. (2020). Multi-objective evolutionary design of antibiotic treatments. *Artificial intelligence in medicine, 102*, 101759.
75. Goranova, M., Ochoa, G., Maier, P., & Hoyle, A. (2022). Evolutionary optimisation of antibiotic dosing regimens for bacteria with different levels of resistance. *Artificial intelligence in medicine, 133*, 102405.
76. Ochoa, G., Christie, L.A., Brownlee, A.E., & Hoyle, A. (2020). Multi-objective evolutionary design of antibiotic treatments. *Artificial intelligence in medicine, 102*, 101759.
77. Kohanski, M.A., Dwyer, D.J., Hayete, B., Lawrence, C.A., & Collins, J.J. (2007). A Common Mechanism of Cellular Death Induced by Bactericidal Antibiotics. *Cell, 130*, 797-810.
78. Melo, M.C., Maasch, J.R., & de la Fuente-Nunez, C. (2021). Accelerating antibiotic discovery through artificial intelligence. *Communications Biology, 4*.
79. Etebu, E., & Arikekpar, I. (2016). Antibiotics: Classification and mechanisms of action with emphasis on molecular perspectives.
80. Paterson, I., Hoyle, A., Ochoa, G., Baker-Austin, C., & Taylor, N.G. (2016). Optimising Antibiotic Usage to Treat Bacterial Infections. *Scientific Reports, 6*.